Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 16/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 7/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | PIK3R2 | O00459 | 7/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16583965 | 1.00 | PIK3CD (0.54) | PIK3CDPIK3CGPIK3R1ABCB11TBXA2R | |
| SCHEMBL14726573 | 0.93 | PIK3CD (0.47) | PIK3CDPIK3CGPIK3R1ABCB11TBXA2R | |
| SCHEMBL16591271 | 0.90 | PIK3CD (0.55) | PIK3CDPIK3CGPIK3R1ABCB11TBXA2R | |
| SCHEMBL14649471 | 0.89 | PIK3CD (0.46) | PIK3CDPIK3CGPIK3R1ABCB11TBXA2R | |
| SCHEMBL22529256 | 0.89 | PIK3CD (0.46) | PIK3CDPIK3CGPIK3R1ABCB11TBXA2R | |
| SCHEMBL30343572 | 0.89 | PIK3CD (0.54) | PIK3CDPIK3CGPIK3R1ABCB11TBXA2R | |
| SCHEMBL152366 | 0.89 | PIK3CD (0.54) | PIK3CDPIK3CGPIK3R1ABCB11TBXA2R | |
| SCHEMBL29440942 | 0.89 | PIK3CD (0.54) | PIK3CDPIK3CGPIK3R1ABCB11TBXA2R | |
| SCHEMBL152365 | 0.89 | PIK3CD (0.54) | PIK3CDPIK3CGPIK3R1ABCB11TBXA2R | |
| SCHEMBL14726577 | 0.87 | PIK3CD (0.44) | PIK3CDPIK3CGPIK3R1ABCB11TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459306-B2 | Compounds, compositions, and methods for treating T-cell acute lymphoblastic leukemia | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-10-04 | — | — | US | disclosed |
| CN-111386264-A | Compounds, compositions and methods for treating T-cell acute lymphoblastic leukemia | 纽约市哥伦比亚大学理事会 | 2020-07-07 | — | — | CN | disclosed |
| US-20200165211-A1 | Compounds, Compositions, and Methods for Treating T-Cell Acute Lymphoblastic Leukemia | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-05-28 | — | — | US | disclosed |
| US-20200165211-A1 | Compounds, Compositions, and Methods for Treating T-Cell Acute Lymphoblastic Leukemia | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-05-28 | — | — | US | disclosed |
| WO-2019028055-A1 | COMPOUNDS, COMPOSITIONALS, AND METHODS FOR TREATING T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | THE TRUSTEES OF COLUMBIA UNIVERISTY IN THE CITY OF NEW YORK (US) | 2019-02-07 | — | — | WO | disclosed |
| US-9738644-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738644-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9718815-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718815-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9657007-B2 | Substituted aminopyrimidine compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLKINE, LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029984-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029984-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| WO-2013012915-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013012918-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| WO-2011146882-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INTELLIKINE, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | PIK3CD 5/4885PIK3CG 14/4885PIK3R1 70/4885 |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | PIK3CD 18/4885PIK3CG 32/4885PIK3R1 119/4885 |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CG 7/4885PIK3R1 27/4885 |
| US-11459306-B2 | Compounds, compositions, and methods for treating T-cell acute lymphoblastic leukemia | BCL9, BCL3, MCL1 | PIK3CD 15/4885PIK3CG 11/4885PIK3R1 28/4885 |
| US-20200165211-A1 | Compounds, Compositions, and Methods for Treating T-Cell Acute Lymphoblastic Leukemia | BCL9, BCL3, MCL1 | PIK3CD 15/4885PIK3CG 11/4885PIK3R1 28/4885 |
| US-20130029984-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CG 7/4885PIK3R1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.